LRRIQ3

Across TCGA pan-cancer cohorts, LRRIQ3 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated LRRIQ3 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher LRRIQ3 Mutation is associated with better overall survival. In most high-consensus cancer types, elevated LRRIQ3 expression acts as an unfavorable survival marker, although some lineages such as SKCM and UCEC show a favorable association.

SKCM, UCEC, and OV are the cancer types where LRRIQ3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	OS	Median	II,III,IV	0.918	0.709	<.001	19	view →
UCEC	DFS	Median	III,IV	0.915	0.528	.028	18	view →
OV	DFS	Median	II,III,IV	0.295	0.543	.028	12	view →
SCLC	OS	Median	All	0.137	0.715	<.001	12	view →
PRAD	DFS	Median	All	0.617	0.886	.026	6	view →
SARC	DFS	Median	All	0.121	0.591	.042	3	view →
BRCA	OS	Median	III,IV	0.161	0.549	.031	2	view →
BLCA	DFS	Median	All	1.000	0.608	.028	1	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

LRRIQ3–SKCM (OS)

Open the SKCM breakdown →